Web Results

Mevalonate kinase deficiency (HIDS) - Wikipedia, the free ...

en.wikipedia.org/wiki/Mevalonate_kinase_deficiency_(HIDS)

The disorder known as mevalonate kinase deficieny (MKD) or mevalonic aciduria or HIDS .... Canakinumab is a long acting monoclonal antibody which is directed against ... Recently, Neven, et al. desc...

Long term management of patients with cryopyrin-associated ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC2727888/

Around 25% of MWS patients developed amyloidosis (Dode et al 2003), with occasional fatal ... and cochlear enhancement, consistent with oedema and inflammation (Neven et al 2008). ..... [PubMed]; Martinon F, Petrilli V, Mayor A, et al.

Long-term efficacy of the interleukin-1 receptor antagonist anakinra ...

www.ncbi.nlm.nih.gov/pubmed/20039428

Neven B(1), Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, Pinto G, Pagnier A, Bodemer C, Bodaghi B, Tardieu M, Prieur AM, Quartier P.

Order List - Supreme Court

www.supremecourt.gov/orders/courtorders/041816zor_2co3.pdf

Apr 18, 2016 ... MORRIS, PEGGY V. SILVESTRE, EDWARD, ET AL. The motion to direct the Clerk to file a petition for a writ of certiorari out of time is denied.

Is It Safe to Treat Endometrial Carcinoma Endoscopically?

jco.ascopubs.org/content/27/32/5305.full

Nov 10, 2009 ... However, in the meta-analysis of Palomba et al, only 172 patients were ... Conception and design: Ignace Vergote, Frederic Amant, Patrick Neven .... vs laparotomy for early stage endometrial cancer: Long-term data of a ...

Influence of gonadotrophin-releasing hormone ... - Instituto Bernabeu

www.institutobernabeu.com/upload/ficheros/enlaces/influence_of_gonadotrophinreleasing_hormone_agonist_total_dose_in_the_ovarian_stimulation_in_the_long_downregulation_protocol_for_invitrofertilization.pdf

total dose in the ovarian stimulation in the long down-regulation protocol ... (GI: 44 and 60% respectively versus Gil: 20% and 25% respectively). ... of GnRH on gonadotrophin secretion (Gordon et al, 1993). 2366 .... (Neven et al, 1987). Similar ...

Blood Journal | SCID patients with ARTEMIS vs RAG deficiencies ...

www.bloodjournal.org/content/123/2/281

Jan 9, 2014 ... ... sequelae). We also analyzed long-term immunologic outcome. ..... Neven B,; Leroy S,; Decaluwe H,; et al . Long-term outcome after ...

Robust Classification with Adiabatic Quantum Optimization - ICML

icml.cc/2012/papers/461.pdf

cent work (Long & Servedio, 2010) showed that convex loss functions ... '2' vs the rest, etc.) The data ... Google (Neven et al., 2009a) and of Lockheed Martin.

Hormone Therapy for Breast Cancer Fact Sheet - National Cancer ...

www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet

Regan MM, Neven P, Giobbie-Hurder A, et al. ... Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study ... Long-term tamoxifen citrate use and potential ocular toxicity.

Low Circulating Natural Killer Cell Counts are Associated With ...

www.sciencedirect.com/science/article/pii/S2352396416300640

Mar 2, 2016 ... 5.9% and 8.3%) and infectious pneumonia (63.6% vs. ... patients is similar to that in patients with normal NK cell counts (Neven et al., 2009). ...... Bodemer and colleagues recently described the long-term persistence of live ...

More Info

Long-Lasting Production of New T and B Cells and T-Cell ... - NCBI

www.ncbi.nlm.nih.gov

Dec 1, 2014 ... However, the presence of graft-versus-host disease and ablative .... The type of immunodeficiency, classified according to Al-Herz et al. ..... of 12 years at two time points (short- and long-term follow-up), while Neven et al.

Order List (12/09/13) - Supreme Court

www.supremecourt.gov

Dec 9, 2013 ... CRISPIN, NEAL V. CIR. 13-188. BAKER, ABASI S. V. UNITED STATES. 13-256. HEGAB, MAHMOUD V. LONG, LETITIA A., ET AL. 13-289.

S1-3: Long-Term Survival Outcomes among Postmenopausal ...

cancerres.aacrjournals.org

Dec 15, 2011 ... S1-3: Long-Term Survival Outcomes among Postmenopausal Women with ... disease-free survival (DFS) vs delayed ZOL (de Boer R, et al.